Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

14.52 -0.99 (-6.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
Via Benzinga
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease. 
Via Investor's Business Daily
Recap: KalVista Pharma Q3 Earnings
Via Benzinga
Insiders Buying Dorian LPG And 2 Other Stocks
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
KalVista Pharma: Q2 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US. 
Via Benzinga
How KalVista Pharma Is Taking On A Rare But Deadly Disease
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday?
Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Insiders Buying Monro And 3 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
3 Micro-Cap Stocks That Could Be Moonshots
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS